Pulmatrix, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Pulmatrix, Inc. - overview
Established
2003
Location
Framingham, MA, US
Primary Industry
Biotechnology
About
Pulmatrix, Inc. is a US-based biotechnology company focusing on developing innovative pulmonary-delivered therapeutics utilizing proprietary technology to enhance patient care for respiratory diseases. Founded in 2003, Pulmatrix, Inc. specializes in therapeutic development for respiratory conditions.
In April 2026, Pulmatrix, Inc. raised approximately USD 1 million in a private placement, selling shares at USD 2. 20 apiece, on Nasdaq. Ted Raad serves as the CEO, guiding the company towards its strategic goals.
PULMATRiX specializes in advanced pulmonary-delivered therapeutics utilizing its proprietary iSPERSE™ technology. This innovative approach focuses on enhancing patient care by providing efficient delivery systems for medications aimed at addressing serious respiratory diseases. The company's core product offerings improve drug absorption in the lungs, optimizing treatment outcomes for conditions such as asthma and chronic obstructive pulmonary disease (COPD). PULMATRiX targets healthcare providers, hospitals, and patients requiring specialized respiratory therapies, primarily marketing its products in North America and Europe.
In the most recent fiscal year of 2022, PULMATRiX reported revenue of USD 6. 07 mn with an EBITDA of USD -17. 40 mn. Revenue is generated through partnerships with healthcare providers and institutions, involving direct sales of its therapeutics and potentially subscription-based models for ongoing supplies, ensuring consistent access to its innovative delivery systems.
Pulmatrix, Inc. plans to expand its product line and enhance market presence by developing new pulmonary-delivered therapeutics, leveraging its iSPERSE™ technology.
Current Investors
Defense Advanced Research Projects Agency, Polaris Partners, 5AM Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.pulmatrix.com/
Company Stage
Mature
Total Amount Raised
Subscriber access only
Pulmatrix, Inc. - timeline of key events
Pulmatrix, Inc. - financials
| Fiscal Year Ended | Mar 31, 2014 | Mar 31, 2015 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | 1,201,000 | 835,000 | 335,000 | 153,000 | 7,910,000 | 12,634,000 | 5,169,000 | 6,071,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | (59.9%) | (54.3%) | 5069.9% | 59.7% | (59.1%) | 17.5% | - | - | - |
| EBITDA (USD) | - | (6,707,000) | (22,786,000) | (24,616,000) | (17,229,000) | (20,100,000) | (19,927,000) | (8,819,000) | (18,931,000) | (17,402,000) | - | - | - |
| Operating Income (USD) | - | (6,708,000) | (23,018,000) | (24,866,000) | (17,475,000) | (20,331,000) | (20,692,000) | (9,862,000) | (20,167,000) | (18,947,000) | - | - | - |
| Operating Margin | - | - | (1916.6%) | (2978.0%) | (5216.4%) | (13288.2%) | (261.6%) | (78.1%) | (390.2%) | (312.1%) | - | - | - |
| % EBITDA Margin | - | - | (1897.3%) | (2948.0%) | (5143.0%) | (13137.3%) | (251.9%) | (69.8%) | (366.2%) | (286.6%) | - | - | - |
| NET Income (USD) | (3,118,000) | (6,691,000) | (26,167,000) | (27,843,000) | (18,056,000) | (20,563,000) | (20,596,000) | (19,308,000) | (20,171,000) | (18,836,000) | - | - | - |
| % Net Margin | - | - | (2178.8%) | (3334.5%) | (5389.9%) | (13439.9%) | (260.4%) | (152.8%) | (390.2%) | (310.3%) | - | - | - |
Pulmatrix, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Merger | Announced | Eos SENOLYTIX, Inc. | - |
Displaying 1 - 1 of 1
Pulmatrix, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.